ERBB2 and breast carcinoma: Interestingly, the use of trastuzumab, an antibody to HER-2 used in the clinic for the treatment of HER-2 positive breast cancers, to deliver sialidase to tumour cells reduced binding to siglec-7 and enhanced NK killing [57].